Have osteoporosis 
Have a 10 yr probability of hip fracture >3% or major fracture >20% based on results of the FRAX tool 
Currently take bisphosphonates, estrogen replacement therapy, glucocorticosteroids, or other drugs affecting bone 
Currently participate in a resistance training or high impact weight bearing exercise program two or more times weekly 
Weigh >300 lbs 
Have abnormal results for the following laboratory tests: serum 25(OH)D; serum creatinine; serum calcium; PTH; TSH 
Have Paget's disease, heart disease, uncontrolled hypertension, renal disease, or other concomitant conditions that prohibit participation in exercises, risedronate therapy, or use of CaD supplements.       
    

NCT02186600_exc_T1
Condition
osteoporosis
NCT02186600_exc_T2
Measurement
10 yr probability of hip fracture
NCT02186600_exc_T3
Condition
hip fracture
NCT02186600_exc_T4
Value
>3%
NCT02186600_exc_T5
Measurement
10 yr probability of major fracture
NCT02186600_exc_T6
Condition
major fracture
NCT02186600_exc_T8
Value
>20%
NCT02186600_exc_T9
Drug
bisphosphonates
NCT02186600_exc_T10
Procedure
estrogen replacement therapy
NCT02186600_exc_T11
Drug
glucocorticosteroids
NCT02186600_exc_T12
Drug
drugs affecting bone
NCT02186600_exc_T14
Condition
participate in a resistance training
NCT02186600_exc_T16
Condition
participate in high impact weight bearing exercise
NCT02186600_exc_T18
Multiplier
two or more times weekly
NCT02186600_exc_T19
Measurement
Weigh
NCT02186600_exc_T20
Value
>300 lbs
NCT02186600_exc_T21
Value
abnormal results
NCT02186600_exc_T22
Measurement
serum 25(OH)D
NCT02186600_exc_T23
Measurement
serum creatinine
NCT02186600_exc_T24
Measurement
serum calcium
NCT02186600_exc_T25
Measurement
PTH
NCT02186600_exc_T26
Measurement
TSH
NCT02186600_exc_T27
Condition
Paget's disease
NCT02186600_exc_T28
Condition
heart disease
NCT02186600_exc_T29
Condition
uncontrolled hypertension
NCT02186600_exc_T30
Condition
renal disease
NCT02186600_exc_T31
Condition
other concomitant conditions that prohibit participation in exercises
NCT02186600_exc_T33
Procedure
risedronate therapy
NCT02186600_exc_T34
Drug
CaD supplements